{"id":295296,"date":"2024-07-15T00:00:00","date_gmt":"2024-07-15T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfhe0003-2024-biopharma-immune-thrombocytopenic-purpura-landscape-forecast-niche-rare-disease\/"},"modified":"2026-03-31T10:29:16","modified_gmt":"2026-03-31T10:29:16","slug":"nrlfhe0003-2024-biopharma-immune-thrombocytopenic-purpura-landscape-forecast-niche-rare-disease-landscape-forecast","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfhe0003-2024-biopharma-immune-thrombocytopenic-purpura-landscape-forecast-niche-rare-disease-landscape-forecast\/","title":{"rendered":"Immune Thrombocytopenic Purpura &#8211; Landscape &#038; Forecast &#8211; Niche &#038; Rare Disease Landscape &#038; Forecast (US\/EU5)"},"content":{"rendered":"<p>Immune thrombocytopenic purpura (<abbr title=\"immune thrombocytopenic purpura\">ITP<\/abbr>) is an autoimmune disease resulting in a low platelet count. Treatment of <abbr title=\"immune thrombocytopenic purpura\">ITP<\/abbr> involves the use of immunomodulators and corticosteroids as well as multiple therapies specifically approved for <abbr title=\"immune thrombocytopenic purpura\">ITP<\/abbr>. Thrombopoietin receptor agonists (<abbr title=\"thrombopoietin\">TPO<\/abbr>&#8211;<abbr title=\"receptor agonist\">RA<\/abbr>s)\u2014orally administered eltrombopag (Novartis\u2019s Promacta \/ Revolade) and avatrombopag (SOBI\u2019s Doptelet) and subcutaneously administered romiplostim (Amgen\u2019s Nplate)\u2014are key treatments for <abbr title=\"immune thrombocytopenic purpura\">ITP<\/abbr>. Rigel Pharmaceuticals \/ Grifols\u2019 oral Tavalisse \/ Tavlesse (fostamatinib), a spleen tyrosine kinase inhibitor, is an option for treatment-refractory or unresponsive chronic <abbr title=\"immune thrombocytopenic purpura\">ITP<\/abbr>. Despite the availability of multiple therapies for <abbr title=\"immune thrombocytopenic purpura\">ITP<\/abbr>, effective treatments are needed for patients who are treatment-refractory or unresponsive to current therapies. Also needed are drugs that do not require chronic administration. Thus, ample commercial opportunity remains for pharmacotherapies with novel mechanisms of action as well as those with curative potential.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What is the size of the diagnosed prevalent newly diagnosed, persistent, and chronic <abbr title=\"immune thrombocytopenic purpura\">ITP<\/abbr> patient populations in the United States and <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr> countries, and how will these populations change through 2033?<\/li>\n<li>How have the <abbr title=\"thrombopoietin\">TPO<\/abbr>&#8211;<abbr title=\"receptor agonist\">RA<\/abbr>s and Tavalisse \/ Tavlesse been incorporated into the <abbr title=\"immune thrombocytopenic purpura\">ITP<\/abbr> treatment algorithm, and what is their commercial potential through 2033?<\/li>\n<li>What factors are driving and constraining market growth? Which new agents and classes of agents will emerge during the forecast period, and what impact will they have on the overall market?<\/li>\n<\/ul>\n<p><strong>Scope<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li><strong>Geography: <\/strong>United States and <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr><\/li>\n<li><strong>Primary research:<\/strong> Six country-specific interviews with thought-leading hematologists; supported by survey data collected for this study<\/li>\n<li><strong>Epidemiology:<\/strong> Diagnosed incidence of <abbr title=\"immune thrombocytopenic purpura\">ITP<\/abbr> by country, diagnosed drug-treated prevalence of <abbr title=\"immune thrombocytopenic purpura\">ITP<\/abbr> by country, diagnosed prevalence of <abbr title=\"immune thrombocytopenic purpura\">ITP<\/abbr> by disease phase by country<\/li>\n<li><strong>F<\/strong><b>orecast: <\/b>Drug-level sales and patient share of key <abbr title=\"immune thrombocytopenic purpura\">ITP<\/abbr> therapies in 2023 and 2033<\/li>\n<li><strong>Drug treatments:<\/strong> Coverage of key current and emerging therapies<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Niche &#038; Rare Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Key feature<\/strong><\/p>\n<p>Niche &#038; Rare Disease Landscape &#038; Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-295296","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hematology","biopharma-geography-us","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295296","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295296\/revisions"}],"predecessor-version":[{"id":575938,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295296\/revisions\/575938"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=295296"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}